2024
Management of postinfectious inflammatory arthritis
Baker H, Amaral J, Schoen R. Management of postinfectious inflammatory arthritis. Current Opinion In Rheumatology 2024, 36: 155-162. PMID: 38411201, DOI: 10.1097/bor.0000000000001009.Peer-Reviewed Original ResearchConceptsTreatment of acute infectionsAcute infectionInflammatory arthritisBenefits of antimicrobial therapyTreatment of infectionsTargeted synthetic DMARDsSpectrum of diseasesRefractory arthritisAntimicrobial therapySynthetic DMARDsFraction of casesTreatment optionsConventional therapyDisease-modifying treatmentsReactive arthritisInflammatory arthritidesInflammatory processPrompt identificationSelf-limitingChronic arthritisArthritisInfectionTreatmentTherapyArthralgiaChikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial
Amaral J, Lucena G, Schoen R. Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial. Current Rheumatology Reviews 2024, 20: 337-346. PMID: 38173199, DOI: 10.2174/0115733971278715231208114037.Peer-Reviewed Original ResearchChronic chikungunya arthritisChikungunya arthritisDouble-blindJoint countPlacebo-controlled clinical trialPain visual analog scalePlacebo-controlled trialChikungunya feverPatient global assessmentVisual analog scaleAffected individualsSwollen joint countTender joint countChikungunya virus infectionDAS28-ESRDexamethasone groupSD ageAnalog scaleBiphasic diseaseTreatment responseClinical trialsAcute phaseDexamethasoneVirus infectionGlobal assessmentBone erosions and joint damage caused by chikungunya virus: a systematic review
Amaral J, Taylor P, Schoen R. Bone erosions and joint damage caused by chikungunya virus: a systematic review. Revista Da Sociedade Brasileira De Medicina Tropical 2024, 57: e00404-2024. PMID: 38597523, PMCID: PMC11000508, DOI: 10.1590/0037-8682-0433-2023.Peer-Reviewed Original ResearchConceptsChronic chikungunya arthritisChikungunya arthritisJoint damageRheumatoid arthritisJoint painDisease-modifying antirheumatic drug therapyBone erosionProgression of radiographic joint damageDisease-modifying antirheumatic drugsSystematic reviewAntirheumatic drug therapyAcute febrile illnessPersistent joint painSimilar to rheumatoid arthritisRadiographic joint damageChikungunya virusYears post-infectionChronic joint damagePrevent joint damageDisease-modifying therapiesJoint structural damageRheumatoid arthritis treatmentAntirheumatic drugsProspective studyChikungunya infectionQuality of Life and Disability in Chikungunya Arthritis
Amaral J, Taylor P, Weinblatt M, Bandeira Í, Schoen R. Quality of Life and Disability in Chikungunya Arthritis. Current Rheumatology Reviews 2024, 20: 65-71. PMID: 37605393, DOI: 10.2174/1573397119666230726113647.Peer-Reviewed Original ResearchConceptsChikungunya arthritisVisual analog scaleSF-12Quality of lifeChikungunya feverVisual analog scale pain scoreShort Form Health SurveyHealth Assessment Questionnaire Disability IndexRetrospective cross-sectional studyVirus-infected patientsCKV patientsCross-sectional studyPublic health impactChikungunya fever patientsChikungunya virus infectionMCS-12PCS-12Assess disabilityOutbreak of chikungunya feverHealth SurveyDisability IndexPain scoresDAS28-ESRAnalog scaleMosquito vectors
2023
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients.
Amaral J, Bingham C, Taylor P, Vilá L, Weinblatt M, Schoen R. Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients. American Journal Of Tropical Medicine And Hygiene 2023, 109: 542-547. PMID: 37549898, PMCID: PMC10484246, DOI: 10.4269/ajtmh.23-0205.Peer-Reviewed Original ResearchConceptsChikungunya arthritisWeeks of treatmentSwollen joint countTender joint countJoint countDAS28-erythrocyte sedimentation rateAge of patientsTreated with methotrexateDisease Activity ScoreGroup of patientsMedical record reviewAcute chikungunyaPain scoresClinical improvementBrazilian patientsAssess painClinical criteriaBaseline visitActivity scoreMaintained 5 monthsPainPatientsRecord reviewSelf-limitingRheumatology practiceBrazil at the Center of Chikungunya Outbreaks
Amaral J, Taylor P, Schoen R. Brazil at the Center of Chikungunya Outbreaks. Journal Of Global Infectious Diseases 2023, 15: 131-132. PMID: 37800080, PMCID: PMC10549908, DOI: 10.4103/jgid.jgid_21_23.Peer-Reviewed Original ResearchExtra-articular Manifestations of Chikungunya
de Oliveira J, Nogueira I, Amaral J, Campos L, Mendonça M, de Brito Ricarte M, de Góes Cavalcanti L, Schoen R. Extra-articular Manifestations of Chikungunya. Revista Da Sociedade Brasileira De Medicina Tropical 2023, 56: e0341-2023. PMID: 38088664, PMCID: PMC10706034, DOI: 10.1590/0037-8682-0341-2023.Peer-Reviewed Original ResearchConceptsExtra-articular manifestationsChikungunya feverAtypical illnessAcute interstitial nephritisAcute anterior uveitisMinority of patientsSelf-limiting conditionAnterior uveitisAbdominal painChronic arthritisCutaneous manifestationsInterstitial nephritisAtypical symptomsUnusual manifestationAtypical featuresTrue diagnosisNatural historyTropical diseasesManifestationsFurther studiesIllnessDiagnosisAffected systemMyocarditisUveitis
2022
Pathogenesis of chronic chikungunya arthritis: Resemblances and links with rheumatoid arthritis
Amaral J, Bingham C, Taylor P, Vilá L, Weinblatt M, Schoen R. Pathogenesis of chronic chikungunya arthritis: Resemblances and links with rheumatoid arthritis. Travel Medicine And Infectious Disease 2022, 52: 102534. PMID: 36549417, DOI: 10.1016/j.tmaid.2022.102534.Peer-Reviewed Original ResearchConceptsChronic chikungunya arthritisMesenchymal stem cellsJoint painChikungunya virusReactivation of dormant virusesMorphologically similar to fibroblastsChikungunya feverEpigenetic changesChronic joint painAcute febrile illnessChikungunya virus infectionSimilar to fibroblastsMaculopapular rashChikungunya arthritisDormant virusesFebrile illnessLatent infectionMultipotent cellsStem cellsHeterogeneous groupRheumatoid arthritisPathogenic hypothesisGroup of multipotent cellsPainPatientsChikungunya Arthritis
Amaral J, Pal T, Schoen R. Chikungunya Arthritis. Rare Diseases Of The Immune System 2022, 179-190. DOI: 10.1007/978-3-031-05002-2_14.Peer-Reviewed Original ResearchDisease-modifying anti-rheumatic drugsAnti-rheumatic drugsInflammatory rheumatic diseasesChikungunya arthritisChronic arthritisSupportive careBiphasic illnessRheumatic diseasesRheumatoid arthritisInflammatory processViral infectionArthritisAlphavirus infectionMillions of peopleIllnessInfectionDiseaseChikungunyaSubtropical worldArthralgiaRashPatientsFeverMethotrexateCare
2020
Lyme disease: diagnosis and treatment.
Schoen R. Lyme disease: diagnosis and treatment. Current Opinion In Rheumatology 2020, 32: 247-254. PMID: 32141956, DOI: 10.1097/bor.0000000000000698.Peer-Reviewed Original ResearchConceptsClinical manifestationsLyme arthritisAdjunctive laboratory testsAcute systemic illnessLyme diseaseDiagnosis of Lyme diseaseTreatment of Lyme diseaseOligo-arthritisUntreated patientsClinical featuresAntibiotic treatmentSystemic illnessRheumatic diseasesInflammatory arthritisTreatment approachesRheumatoid arthritisDiagnostic testsPatientsArthritisDiseaseManifestationsTreatmentVector-borne infectionsLaboratory testsLymeChallenges in the Diagnosis and Treatment of Lyme Disease
Schoen R. Challenges in the Diagnosis and Treatment of Lyme Disease. Current Rheumatology Reports 2020, 22: 3. PMID: 31912251, DOI: 10.1007/s11926-019-0857-2.Peer-Reviewed Original ResearchConceptsTreatment of Lyme diseaseClinical featuresCourse of oral antibiotic therapyOral antibiotic therapyLate-stage manifestationLate-stage diseaseLyme diseaseAntibiotic therapyCausative organismTreatment strategiesClinical expressionLyme arthritisImpact of Lyme diseaseDiagnosisDiseasePatientsTreatmentVector-borne illnessStrains of Borrelia burgdorferiLymeWell-characterizedMorbidityTherapyFindingsIt
2018
Successful Methotrexate Treatment of Chronic Chikungunya Arthritis
Amaral J, Bingham C, Schoen R. Successful Methotrexate Treatment of Chronic Chikungunya Arthritis. JCR Journal Of Clinical Rheumatology 2018, 1. DOI: 10.1097/00124743-900000000-99120.Peer-Reviewed Original Research
2013
Editorial Commentary: Better Laboratory Testing for Lyme Disease: No More Western Blot
Schoen R. Editorial Commentary: Better Laboratory Testing for Lyme Disease: No More Western Blot. Clinical Infectious Diseases 2013, 57: 341-343. PMID: 23592831, DOI: 10.1093/cid/cit238.Peer-Reviewed Original ResearchMonoarthritis risk stratification in Lyme disease
Schoen R. Monoarthritis risk stratification in Lyme disease. Nature Reviews Rheumatology 2013, 9: 261-262. PMID: 23567460, DOI: 10.1038/nrrheum.2013.47.Peer-Reviewed Original Research
2011
Emerging Viral Infections in Rheumatic Diseases
Khasnis A, Schoen R, Calabrese L. Emerging Viral Infections in Rheumatic Diseases. Seminars In Arthritis And Rheumatism 2011, 41: 236-246. PMID: 21440932, DOI: 10.1016/j.semarthrit.2011.01.008.Peer-Reviewed Original ResearchConceptsRheumatic diseasesViral pathogensMyriad clinical featuresHuman immunodeficiency virusNew viral pathogensBetter preventive strategiesParticular clinical relevanceRheumatic manifestationsRheumatologic manifestationsHepatitis BCase seriesClinical featuresImmunodeficiency virusEpidemiologic factorsCase reportEarly recognitionPreventive strategiesChikungunya virusClinical relevanceViral infectionInfectious diseasesDiseaseRheumatologistsCorrect treatmentOriginal report
2007
Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis
Pal U, Wang P, Bao F, Yang X, Samanta S, Schoen R, Wormser GP, Schwartz I, Fikrig E. Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. Journal Of Experimental Medicine 2007, 205: 133-141. PMID: 18166585, PMCID: PMC2234379, DOI: 10.1084/jem.20070962.Peer-Reviewed Original ResearchConceptsLyme arthritisMouse jointsB. burgdorferi antigensBurgdorferi-infected miceSevere arthritisSpirochete numbersArthritisHost responseLyme diseaseAffinity-purified antibodiesBorrelia burgdorferiChain reactionMiceOriginal phenotypeBasic membrane proteinMutant spirochetesGene expressionJointsInflammationPathogenesisAntigenDiseaseB. burgdorferi gene expression
2005
A comparison of two treatment regimens of ceftriaxone in late Lyme disease
Dattwyler R, Wormser G, Rush T, Finkel M, Schoen R, Grunwaldt E, Franklin M, Hilton E, Bryant G, Agger W, Maladorno D. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wiener Klinische Wochenschrift 2005, 117: 393-397. PMID: 16053194, DOI: 10.1007/s00508-005-0361-8.Peer-Reviewed Original ResearchConceptsLate Lyme diseaseDays of therapyLyme diseaseSerologic criteriaClinical cure rateMulti-center studyEvaluable patientsOpen labelAdverse eventsClinical responseClinical subsetsTreatment failureTreatment regimensCure rateEntry criteriaObjective abnormalitiesSerologic resultsSerologic reactivityPatientsLast evaluationOptimal durationCeftriaxoneDiseaseTherapyBorrelia burgdorferi
2003
Asymptomatic Infection with Borrelia burgdorferi
Steere A, Sikand V, Schoen R, Nowakowski J. Asymptomatic Infection with Borrelia burgdorferi. Clinical Infectious Diseases 2003, 37: 528-532. PMID: 12905137, DOI: 10.1086/376914.Peer-Reviewed Original Research
2000
The Lyme disease vaccine: conception, development, and implementation.
Thanassi W, Schoen R. The Lyme disease vaccine: conception, development, and implementation. Annals Of Internal Medicine 2000, 132: 661-8. PMID: 10766685, DOI: 10.7326/0003-4819-132-8-200004180-00009.Peer-Reviewed Original ResearchSafety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials